^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Uterine Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma
Published date:
09/07/2023
Excerpt:
T-DXd showed tumor growth suppression in in vivo USC PDX models that overexpress HER2 at 3+ levels, prolonging survival when compared to controls, with minimal toxicity.
DOI:
10.1158/1535-7163.MCT-23-0126